1 results
Approved WMOPending
The primary objective is to investigate the effect of bepranemab (45mg/kg and 90mg/kg Q4W) vs placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), a scale used to quantify the severity of symptoms of dementia, as the change from…